Bill & Melinda Gates Foundation Provides $55 Million for Phase IIb Trial of MTBVAC Vaccine Against Tuberculosis
IAVI, a global non-profit scientific research organization, and the Spanish biopharmaceutical company Biofabria subsidiary of the Zendal group, announced yesterday that the Bill & Melinda Gates Foundation has granted them 55 million dollars to carry out the Phase IIb trial that evaluates the safety and efficacy of the MTBVAC vaccine, a candidate against tuberculosis (TB). … Read more